Vogt-Koyanagi-Harada syndrome …

Homer Chiang MD

Neuro-Ophthalmology & Neuro-Otology

Updated 06.23.2024
Released 05.14.1996
Expires For CME 06.23.2027

Vogt-Koyanagi-Harada syndrome

Author: Homer Chiang MD

See Contributor Disclosures

Editor: Jonathan D Trobe MD

Vogt-Koyanagi-Harada syndrome

In This Article

Quick Link

Introduction

Overview

Vogt-Koyanagi-Harada syndrome is an inflammatory condition in which uveitis is the most significant feature of the illness. Neurologists may be called on to diagnose the prodromal phase of the disease in which the predominant symptoms are headache, meningeal signs, and, less often, focal neurologic findings. CSF pleocytosis is also common. In this update, the authors cite data demonstrating that earlier initiation of either glucocorticoids or immunomodulatory measures is associated with a reduction in late visual morbidity and that the neurologic manifestations can include cerebral ischemia.

Key points

	• Vogt-Koyanagi-Harada syndrome is primarily an ocular inflammatory disease, but the prodrome often includes signs and symptoms that bring the patient to a neurologist, including headache, meningeal signs, and CSF pleocytosis.
	• Melanin pigment-containing cells are most often targeted, including the retinal pigment epithelium, producing chorioretinitis (uveitis); cutaneous melanocytes, producing vitiligo and poliosis; and the organ of Corti, producing sensorineural hearing loss.
	• The disease is encountered more frequently in persons of Asian, Latin, and Mediterranean descent.

Historical note and terminology

Vogt-Koyanagi-Harada syndrome is a condition in which pigmentary alterations in various tissues are associated with ocular and meningeal inflammation. The combination of poliosis (the graying, or whitening, of a shock of scalp hairs, from the Greek for "gray"), and ocular inflammation was noted by the Arab physician Ali Ibn Isa (Ali ben Issa), who died in 1010 (141; 112), and by others including Vogt (183). Both Vogt and Koyanagi described cases that included the combination of primarily anterior uveitis (bilateral iridocyclitis) with non-ocular manifestations, including pigment loss from skin (vitiligo), hair, and lashes (poliosis); hair loss (alopecia); and hearing loss with tinnitus (183; 88). Koyanagi's six cases were described in 1929, but in 1926, Harada had described similar non-ocular manifestations together with a primarily posterior uveitis characterized by exudative retinal detachments, as well as pleocytosis in the cerebrospinal fluid (50). Moorthy and colleagues credit Babel (18), and Bruno and McPherson (23) with recognizing the essential unity of the cases described by Vogt, Koyanagi, and Harada (112). Herbort and Mochizuki reviewed the historical development of the syndrome, emphasizing that both Koyanagi and Harada perceived the inherent unity of cases with seemingly disparate multisystem signs and symptoms, whereas Vogt was lucky enough to describe the first case extremely well (54).

Clinical manifestations

Presentation and course

Most authors agree that the disease can be divided into four stages: (1) prodromal, (2) uveitic, (3) convalescent, and (4) chronic recurrent. However, the time at which the various manifestations occur is somewhat variable (105; 112). Although the disease-defining symptoms and signs are ophthalmic, they are rare in the prodromal phase, during which time neurologic symptoms predominate. Therefore, patients may initially present for neurologic care.

Prodromal phase. Central nervous system signs and symptoms are most common during the prodromal phase, which lasts a few days. Symptoms of meningeal irritation are the most common. Sugiura noted that a patient's hair and skin might be sensitive to touch during the prodromal stage (171).

Though rare, the central nervous system signs and symptoms during this prodromal phase may be severe, including alteration of cognitive function, confusional state, or psychosis. Focal findings, such as hemiparesis or generalized weakness with loss of sphincter control, or cranial nerve palsy (most commonly of the fifth, sixth, and seventh cranial nerves), are uncommon (141). Seizures and coma may occur rarely in the early stages, usually with more precipitous onset (28; 84). Analyzing a group of 87 patients with Vogt-Koyanagi-Harada syndrome in South India, Mondkar and colleagues found that 64% had non-ocular symptoms at presentation, and of these, 96% had meningismus (111). Continuous diffuse headache lasting several months without other ocular or neurologic findings or symptoms may also be the presenting symptom (87).

CSF pleocytosis is even more common than symptomatic meningitis, with CSF pleocytosis being recorded in about 80% of patients who underwent lumbar puncture (132; 106; 62).

CSF total protein is often normal or mildly elevated, and glucose is usually normal (106; 62). The presence of melanin-laden macrophages in CSF can distinguish Vogt-Koyanagi-Harada syndrome from other conditions, such as syphilis, that produce CSF pleocytosis (80).

Because CSF pleocytosis can be present in patients with minimal or no neurologic findings, it is reasonable to consider that MRI manifestations of meningeal inflammation may provide a sensitive and non-invasive indicator for early diagnosis (49; 103). Thus, finding MRI evidence of either leptomeningitis or pachymeningitis may prove to be a non-invasive surrogate for CSF pleocytosis in early diagnosis of Vogt-Koyanagi-Harada syndrome.

Pattison noted the occasional presence of optic nerve swelling (141), but additional reports in which lumbar puncture was carried out on a large number of patients have generally documented normal opening pressure or, at most, mild elevation (62). In his review, Fishman also noted that, in some series, up to a quarter of the patients may have mild elevation of CSF pressure, but most reports indicate smaller percentages (42). There may also be optic disc swelling due to inflammation as discussed in the Ophthalmic manifestations section (below).

Transient dizziness and nystagmus were observed in about 60% of patients and were suggested to be secondary to labyrinthitis (133). This was later attributed to disease involvement of inner ear melanocytes (82).

Rare associations with Vogt-Koyanagi-Harada syndrome include ischemic stroke, myelopathy with enhancing lesions in the cervical cord (47), and Guillain-Barré syndrome. They appear within weeks to months of the initial symptoms (119).

Uveitic phase. Ophthalmic manifestations become apparent during the uveitic phase. The most common symptom in the uveitic phase is blurred vision, mostly from the cloudy opacity of the ocular refractive media (cornea, aqueous humor, crystalline lens, and vitreous humor). Reduction of visual acuity may also result from serous detachment of the macula. In about a third of cases, the disease starts symptomatically in one eye, but the interval to involvement of the second eye is usually just a few days. In a study of 16 patients, all had decreased visual acuity, abnormal color vision, and abnormal visual fields at the initial visit (194).

During the uveitic phase, which typically lasts several weeks, there is a bilateral posterior uveitis, with elevation of the retina and choroid around the optic disc, optic disc swelling, retinal edema, and serous retinal detachments. The retinal edema and retinal detachments are characteristically multifocal and may increase in number. Pigment epithelial detachment has also been described (78). Non-necrotizing granulomas consisting of epithelioid histiocytes (Dalen-Fuchs nodules) accumulate underneath the retinal pigment epithelium.

Early uveitic phase of Vogt-Koyanagi-Harada syndrome (fundus photograph)

The optic disc is swollen, and there is subretinal fluid extending to the macula. Extensive patches of retinal edema (white) extend along the upper and lower vascular arcades. (Contributed by Dr. James Goodwin.)

Inflammation eventually spreads to involve the anterior segment and is manifest by inflammatory cells and flare in the aqueous humor. White-to-yellow greasy inflammatory precipitates (“mutton fat keratoprecipitates”) may be seen on the corneal endothelial surface. Inflammatory nodules may similarly accumulate at the pupil margin (Koeppe nodules) or on the iris surface (Busacca nodules). These are best seen on slit lamp examination in the ophthalmologist’s office. Caution should be exercised when assessing the pupil in eyes with active intraocular inflammation as posterior synechiae can give the appearance of an irregular or fixed pupil. Patients with anterior segment inflammation may experience decreased visual acuity and significant photophobia.

Eye in the early uveitic phase of Vogt-Koyanagi-Harada syndrome

Elevated protein content of the aqueous humor shows as generalized cloudiness behind the cornea (flare). Mutton-fat type grayish white precipitates are visible on the inner surface of the cornea (within the pupil) and on the iris ...

Optic disc swelling can result during the uveitic phase through a variety of mechanisms, including elevated intracranial pressure, inflammation, and ischemia. Some of these patients may have persistent visual field defects after resolution of swelling due to ischemic optic neuropathy (122; 121).

Acutely elevated intraocular pressure can occur and is characterized by intense ocular pain, perilimbal conjunctival injection (“ciliary flush”), a mid-dilated pupil, and corneal edema. This is a medical emergency, and these patients should be referred to an ophthalmologist without delay. Both acute and subacute elevations in intraocular pressure can cause irreversible damage to the optic nerves. Elevated intraocular pressure is attributable to plugging of the trabecular meshwork by inflammatory cells, thereby reducing aqueous outflow. Alternatively, adhesions between the iris and the anterior capsule of the crystalline lens (posterior synechiae) may impede the flow of aqueous between the ciliary body and cause the iris to bow forward (“iris bombe”). Anterior displacement of the ciliary-iris complex by inflammatory infiltrates may also lead to appositional angle closure. Long-term use of topical and systemic steroid medications increases the risk of steroid-induced ocular hypertension in the subgroup of patients who are “steroid responders.” Glaucoma may persist beyond the resolution of the uveitic phase. In one study, uveal effusion (abnormal fluid distention of the choroid) and an increased number of clinical recurrences of ocular inflammation were significant risk factors for the development of glaucoma (137).

Convalescent phase. This phase lasts several months and is characterized by depigmentation in the skin and choroid. Loss of pigment in the choroid results in a shift of the background fundus color from the usual dusky red to a bright orange, which has been called "sunset glow fundus." There is often clumping of the retinal pigment in the pigment epithelial layer, which results in dense pigmented accumulations alternating with lighter areas throughout the posterior pole of the fundus. It is also during this convalescent phase that depigmentation of the skin (vitiligo) and of the hair on the eyebrows, eyelashes, and scalp (poliosis) occur. The vitiligo affects the head, trunk, and sacrum.

Convalescent phase of Vogt-Koyanagi-Harada syndrome (fundus photograph)

The optic disc is still somewhat swollen. Dense irregular bands of pigment clumping within the retinal pigment epithelium surround the disc. An area of orange discoloration from loss of melanin in the pigment epithelium is seen ju...

Many ophthalmic symptoms improve during the convalescent phase. Visual acuity and color vision may improve as early as 1 to 3 months after presentation, but visual field defects may not improve substantially until 6 months after presentation. Nearly 30% of patients retain visual field impairment 12 months after treatment onset (194).

Chronic recurrent phase. After several months of convalescence, a chronic recurrent phase may set in, manifested by low-grade panuveitis punctuated by acute episodes of predominately anterior uveitis. Choroidal or other uveal neovascularization may arise, leading to edema, hemorrhage, or serous retinal detachment. These phenomena may lead to vision loss, macular scarring, and pigmented perivascular atrophy (149).

Prognosis and complications

HLA-DR4 gene variations may play a role in determining the clinical course, and that the presence of DRB1*0405, DRB1*0410, or both, is associated with a more protracted course (64; 65). Additional studies have shown that patients with HLA-DQA1*0301 and HLA-DQB1*0401 markers are more susceptible to Vogt-Koyanagi-Harada syndrome and HLA-DQA1*0103, 0401, 0501, and that HLA-DQB1*0301, 0402, 0601, 0603 may be protective (101).

Early treatment may improve prognosis, decreasing the number of uveitic flares and the risk of subretinal fibrosis (159). In the face of a poor response to corticosteroid therapy, early initiation of immunomodulatory therapy may improve visual outcome (182).

In a study of 23 patients, older age and presence of non-ocular findings were suggestive of higher rate of recurrence (77).

Complications. The neurologic signs and symptoms are most often limited to the prodromal phase of the disease, when cognitive dysfunction and headache characteristically occur.

Ocular complications include cataract (33% to 42%), glaucoma (24% to 27%), posterior synechiae, choroidal neovascular membrane (11%), subretinal scarring (6%), and optic neuropathy (112; 111; 155; 11).

Increased axial length leading to myopia progression has been described in the Japanese population, occurring as early as 1 month after onset and persisting at 6 months (175; 117).

Clinical vignette

A 16-year-old Hispanic boy developed new headaches for 2 weeks prior to admission. He also noted blurred vision in his right eye and described images as looking distorted and enlarged when viewed with his right eye. On the day of admission, he was confused and disoriented.

Neurologic examination disclosed mental confusion and mild disorientation in time, but no focal findings. There was moderate nuchal rigidity, and Kernig and Brudzinski signs were present. Visual acuity was 20/60 in the right eye and 20/20 in the left eye. There was no relative afferent pupillary defect. Fundus examination revealed serous elevation of the macula in the right eye and optic disc swelling in both eyes.

MRI showed mild patchy gadolinium enhancement of the meninges, but no focal signal abnormalities or ventriculomegaly.

Lumbar puncture yielded clear cerebrospinal fluid under normal opening pressure. There were 60 white blood cells/mm3, of which 95% were lymphocytes and 5% were monocytes. Protein was 56 mg/dl and glucose 40 mg/dl (serum glucose 120 mg/dl). Cytology was negative for malignant or atypical cells. Protein electrophoresis revealed mild elevation of gamma globulin.

He was initially treated with intravenous methylprednisolone 1 gram/day for 3 days, followed by oral prednisone at an initial dose of 60 mg/day, followed by a tapering schedule over the next 3 weeks. His mental status cleared rapidly, and he was discharged to his home after 5 days.

At the first office follow-up visit 2 weeks after discharge, the right eye visual acuity had improved to 20/25 and the symptom of blur and metamorphopsia had resolved. On fundus examination, the optic disc swelling had resolved in both eyes, as had the subretinal fluid at the right macula. At 3 months after presentation, with corticosteroids discontinued, vision and neurologic status remained normal. The fundus exam showed patches of orange discoloration in the posterior pole and some broad bands of pigment clumping and dark discoloration at the level of the retinal pigment epithelium.

Biological basis

Etiology and pathogenesis

Vogt-Koyanagi-Harada syndrome represents a cell-mediated autoimmune response against melanocytes. Histopathologically, inflammation and loss of melanin-containing cells in the skin and the uvea of the eye have been observed. Melanocytes exist in the meninges and in the inner ear; however, the pathogenesis of hearing loss is unresolved.

The histopathology of Vogt-Koyanagi-Harada syndrome has been sparsely documented. There is granulomatous or non-granulomatous choroidal infiltration, with the epithelioid cells often containing cytoplasmic melanin. The choriocapillaris is typically spared (142; 112). Because the available pathologic material comes from enucleated eyes, the only pathology in the central nervous system is the observation of lymphocytic infiltration in the leptomeninges along the amputated stump of the optic nerve (142).

Cellular immune mechanisms are probably more important than humoral ones (112). Antibodies to a number of retinal antigens have been detected, but whether they are epiphenomena is uncertain (25).

Melanocytes are likely involved in the meningitic component. Peripheral and cerebrospinal fluid lymphocytes from patients with Vogt-Koyanagi-Harada syndrome exhibit cytotoxicity against melanoma cells and normal melanocytes (107; 129), as have lymphocytes derived from intraocular aqueous humor (130). Macrophages containing melanin granules have been found in the CSF of patients with Vogt-Koyanagi-Harada syndrome but not in patients with other meningeal inflammatory diseases (120).

In a study, T-cells constituted the majority of lymphocytes in aqueous humor, and aqueous humor lymphocytes from the patients with Vogt-Koyanagi-Harada syndrome were more activated than were peripheral blood lymphocytes. Of the lymphokines studied, interleukin-6 appeared to play an important role as an inflammatory mediator (130). Studies of enucleated eyes from a patient with active Vogt-Koyanagi-Harada syndrome showed similar distribution of T-cell subsets in the inflammatory lesion within the uveal tract (75). Studies have also shown that the ratio of T-helper to T-suppressor cells is increased, and that cells expressing surface markers characteristic of both early (CD25) and late (CD26) lymphocyte activation are present in the inflammatory lesion. Also, a class 2 major histocompatibility complex was expressed in the choroidal melanocytes, as well as in the endothelium of the choriocapillaris, indicating a probable primary role for the melanocyte in the pathogenesis of the lesion (158).

The antigens MART-1/Melan-A (170), peptidase (85), P-36 (128), tyrosinase (192; 45), IgG anti-lens epithelium-derived growth factor (191), and KU-MEL-1 (135) have also been implicated.

In a study of T-helper cells from nine patients with Vogt-Koyanagi-Harada disease versus nine controls, it was found that peripheral blood mononuclear cells from patients produced significantly higher levels of mRNA only for interferon-gamma and not for interleukin-2 or interleukin-4. Levels of interferon-gamma and interleukin-2 were significantly increased in the stimulated cell culture supernatant of patients as compared with controls (60). IgE levels were correlated with retinal disease severity in a study of 128 patients (70).

One study described three patients who developed Vogt-Koyanagi-Harada syndrome shortly after skin injuries (151). All three patients developed vitiligo in the injured areas as the skin healed, and the uveitis began at the same time. The authors suggest that the onset of Vogt-Koyanagi-Harada syndrome following skin injury supports the idea that the disease involves systemic sensitization to shared melanocytic antigens (151). Another study described a 68-year-old Chinese woman who developed uveitis followed by generalized cutaneous inflammation (erythroderma) 6 months later and by vitiligo 6 months after that, the first report of cutaneous inflammation preceding vitiligo (189).

A Vogt-Koyanagi-Harada–like syndrome has been described in patients with metastatic melanoma following initiation of checkpoint inhibition or protein kinase inhibition therapy (44; 201; 29; 22).

A similar syndrome has also been described following vaccination (33; 166; 116), suggesting an exuberant immune reaction as a possible trigger. During the 2020 COVID-19 pandemic, there were several reports of a Vogt-Koyanagi-Harada–like syndrome associated with COVID-19 vaccination (86; 06; 31; 74; 81) and infection (200). There was a relapse of VKH following COVID-19 vaccination (118).

Investigators have identified a subset of pathologically activated monocytes with gene expression indicative of inflammation, antiviral activity, and pathologic activation (57). Peripheral blood mononuclear cells in Vogt-Koyanagi-Harada syndrome have also been shown to express unique RNA profiles (48). Genome-wide association analysis has also identified new loci associated with Vogt-Koyanagi-Harada syndrome risk (147). Studies have identified a set of hub genes that may contribute (186). Proteomic profiling demonstrated increased levels of carbonic anhydrase 2 and Ras-related protein Rap-1b (206) and C1QB (205) in plasma exosomes.

Studies have shown differences in gut microbiota in patients with Vogt-Koyanagi-Harada syndrome compared to healthy controls and other noninfectious anterior uveitides (95; 94; 185).

In a case report, Maehira and colleagues observed different severities of inflammation between the eyes of a single patient with significantly different axial lengths (104).

Using a retinal pigment epithelium model derived from Vogt-Koyanagi-Harada peripheral mononuclear cells, one study observed barrier and phagocytic dysfunction as well as depigmentation compared to normal controls, suggesting dysfunction at the level of the retinal pigment epithelium (96). In the same study, treatment with a molecule targeting early growth response gene 2 restored barrier and phagocytic function in the pathological retinal pigment epithelium cells, suggesting a pathological role and a possible target for future pharmaceutical treatment. Patients with Vogt-Koyanagi-Harada syndrome were also shown to harbor a mutation in membrane palmitoylated protein 2 (MPP2), associated with cytokine and cellular barrier dysfunction (102). Possible contributory polymorphisms in PRKCD, CARD9 (208), ZC3HAV1 (190), OR11H1 (97), and LRRC30 dysregulation (204) have also been identified. Bioinformatics analysis has identified interferon gamma and interleukin 6 as key mediators of Vogt-Koyanagi-Harada syndrome and as possible targets for future therapeutics (27).

Differential diagnosis

Confusing conditions

Sympathetic ophthalmia is an autoimmune condition that closely mimics Vogt-Koyanagi-Harada syndrome. A bilateral non-necrotizing granulomatous uveitis, it is an autoimmune response against uveal autoantigens exposed by penetrating trauma or surgery. Non-ocular manifestations are far fewer in sympathetic ophthalmia than in Vogt-Koyanagi-Harada syndrome (193). A negative history of ocular trauma or surgery makes a diagnosis of sympathetic ophthalmia highly unlikely.

Lymphoma can present simultaneously in the eye and in the brain as a space-occupying lesion or diffuse meningeal infiltration (83; 112; 15; 188). Subretinal deposits, as well as vitreous cells, may be seen. The vitritis may initially respond to corticosteroid therapy but will recur once treatment is stopped. Multiple serous retinal detachments have also been reported (93). Acute lymphoblastic leukemia (52) and lymphoma (114) presenting as Vogt-Koyanagi-Harada syndrome have also been described.

Sarcoidosis is another granulomatous cause of panuveitis. Ocular sarcoidosis tends to produce retinal perivenous sheathing, called "candle-wax drippings," whereas the serous retinal detachment characteristic of Vogt-Koyanagi-Harada syndrome is not encountered. The neurologic findings in sarcoidosis are focal, often involving the cranial nerves, whereas headache and cognitive impairment are most common in Vogt-Koyanagi-Harada syndrome. Both conditions may have chronic CSF pleocytosis (112).

A rare, immune complex–mediated choroidal vasculitis in systemic lupus erythematosus mimics Vogt-Koyanagi-Harada syndrome by causing serous retinal detachments (67; 112). Patients often exhibit systemic manifestations of systemic lupus erythematosus.

Infectious posterior uveitis, including syphilis and tuberculosis, can present as subretinal nodules, posterior or anterior uveitis, and serous retinal detachment. Infection must be ruled out prior to starting corticosteroid or other immunomodulating therapy (100; 01).

Other diseases in the differential diagnosis of Vogt-Koyanagi-Harada syndrome include acute multifocal placoid pigment epitheliopathy, multiple evanescent white dot syndrome, posterior scleritis (163), Behcet disease (76), and bilateral diffuse melanocytic proliferation (30). The two features that most reliably distinguish Vogt-Koyanagi-Harada syndrome from these other forms of uveitis are exudative retinal detachment in the acute uveitic phase and sunset glow fundus in the late phases (150).

Central serous retinopathy typically presents with subretinal fluid and may be recurrent. Central serous retinopathy may be distinguished from Vogt-Koyanagi-Harada syndrome by the lack of uveitis and characteristic leakage pattern on fluorescein angiography. Importantly, central serous retinopathy is typically exacerbated by systemic corticosteroid treatment (126).

With the advent of antineoplastic immune checkpoint inhibitors, a Vogt-Koyanagi-Harada–like syndrome has been described, even after their discontinuation (124; 178). Of the adverse reactions reported in the WHO international pharmacovigilance database, immune checkpoint inhibitors and protein kinase inhibitors were associated with a Vogt-Koyanagi-Harada–like syndrome (16).

A case of Vogt-Koyanagi-Harada–like syndrome preceding melanoma-associated retinopathy has been reported in a patient with metastatic melanoma (124).

Vogt-Koyanagi-Harada syndrome has been described after COVID-19 infection and vaccination (125; 161; 200; 198).

Vogt-Koyanagi-Harada syndrome has been described in patients with autoimmune diseases, including ulcerative colitis (41), IgA nephropathy (203), and erosive seronegative polyarthritis (134), suggesting an association with autoimmunity. A case of Vogt-Koyanagi-Harada disease has been reported as a complication of treating hepatitis C with interferon alpha-2b and ribavirin combination therapy (172).

Associated or underlying disorders

Vogt-Koyanagi-Harada syndrome is associated with HLA-DR4 positivity (64; 65; 165; 187; 146; 157) and HLA-DQ4 (83% vs. 32% in controls). Among variants, HLA-DQA1*0301 positivity is associated with the Vogt-Koyanagi-Harada syndrome phenotype, whereas HLA-DQB1*0604 is considered protective. The DRB1*0405 or DRB1*0410 variants portend to a longer disease course (64; 65). One epigenetic association study of 160 patients identified methylation in HLA-DRB1 and HLA-DQA1, as well as several non-HLA methylation sites (169).

Seven of 62 clones from patients with Vogt-Koyanagi-Harada disease that were reactive with tyrosinase or tyrosinase-related protein showed proliferative responses to peptides that match the motif of the strong binding site for HLADRB1*0405 (45). Weisz and colleagues determined human leukocyte antigen specificities in 25 Hispanic patients living in Southern California and compared them to 217 healthy Hispanic control subjects (187). HLA-DR4 was present in 56% of the patients and in 29% of the control subjects. HLA-DR1 was present in 36% of the patients and in 9% of the control subjects. Combinations of HLA-DR4 and HLA-DR1 characterized 84% of patients but only 35% of control subjects. These findings point to a common immunogenic predisposition to Vogt-Koyanagi-Harada syndrome among different racial groups that are differentially susceptible and that there may be a common epitope shared by DR1 and DR4 that is involved in the pathogenesis of the disease.

In studies examining BRAF-mutant melanoma patients treated with BRAF kinase inhibitors and MEK kinase inhibitors (12), or checkpoint inhibitors for other malignancies (177), the incidence of Vogt-Koyanagi-Harada-like syndrome was higher in those with HLA-DRB1*04 and HLA-DRB1*04:05, respectively.

Diagnostic workup

Diagnostic criteria. Consensus criteria developed in 1978 by the American Uveitis Society were updated following the First International Workshop on Vogt-Koyanagi-Harada Disease in 1999. This newer set of criteria recognizes that Vogt-Koyanagi-Harada has distinct features in different stages of the natural history and establishes criteria for early diagnosis when many of the characteristic cutaneous findings have not yet occurred (154) (Table 1).

Table 1. Consensus Diagnostic Criteria for Vogt-Koyanagi-Harada Disease

Complete Vogt-Koyanagi-Harada disease (criteria 1 to 5 must be present)
	1. No history of penetrating ocular trauma or surgery preceding the initial onset of uveitis
	2. No clinical or laboratory evidence suggestive of other ocular disease entities
	3. Bilateral ocular involvement (a or b must be met, depending on the stage of disease when the patient is examined).
	4. Neurologic and auditory findings (may have resolved by time of examination)
		- meningismus - tinnitus - cerebrospinal fluid pleocytosis
	5. Integumentary finding (not preceding onset of central nervous system or ocular disease)
		- alopecia - poliosis - vitiligo
Early manifestations of disease
	• There must be evidence of a diffuse choroiditis (with or without anterior uveitis, vitreous inflammatory reaction, or optic disc hyperemia), which may manifest as one of the following:
		- focal areas of subretinal fluid - bullous serous retinal detachments
	• With equivocal fundus findings, both of the following must be present as well:
		- focal areas of delay in choroidal perfusion, multifocal areas of pinpoint leakage, large placoid areas of delay in choroidal perfusion, pooling within subretinal fluid, and optic nerve staining by fluorescein angiography
		- diffuse choroidal thickening, without evidence of posterior scleritis by ultrasonography
Late manifestations of disease
	• History suggestive of prior presence of findings
	• Ocular depigmentation (either of the following manifestations is sufficient):
		- sunset glow fundus - Sugiura sign
	• Other ocular signs:
		- nummular chorioretinal depigmented scars - retinal pigment epithelium clumping or migration - recurrent or chronic anterior uveitis
Incomplete Vogt-Koyanagi-Harada disease (criteria 1 to 3 and either 4 or 5 must be present)

Probable Vogt-Koyanagi-Harada disease (isolated ocular disease; criteria 1 to 3 must be present)
(154)

New diagnostic criteria were proposed in 2018 using retrospective data from 1257 Chinese patients in China (195). The criteria consisted of a 3-class model grouping patients into early-phase disease, late-phase disease, or non-Vogt-Koyanagi-Harada uveitis. They compared 37 variables, 21 of which were deemed important in the diagnosis of Vogt-Koyanagi-Harada disease as they were associated with high-specificity or high-positive rates (Table 2). The Diagnostic Criteria for Vogt-Koyanagi-Harada Disease showed higher sensitivity (94.6% vs. 71.9%) and negative predictive value (94.3% vs. 76.6%) than the revised diagnostic criteria. The positive predictive value showed no difference when compared to the revised diagnostic criteria. As these criteria were developed retrospectively, they need to be evaluated in prospective studies for further investigation (195).

Table 2. Proposed New Diagnostic Criteria for Vogt-Koyanagi-Harada Disease

A. No history of penetrating ocular trauma or intraocular surgery preceding the initial onset of uveitis
B. Bilateral ocular involvement (time interval between the two eyes should be 2 weeks)
C. No evidence of infectious uveitis or accompanying systemic rheumatic diseases or evidence suggestive of other ocular disease entities
D. Early-phase Vogt-Koyanagi-Harada disease:
	1. Signs of diffuse choroiditis and exudative retinal detachment
	2. Serous retinal detachment on optical coherence tomography or B-scan ultrasonography
	3. Choroidal thickening on enhanced depth imaging-optical coherence tomography (B-scan can be used where enhanced depth imaging-optical coherence tomography not available, though it is not as precise)
	4. Early punctate staining and late subretinal dye pooling on fluorescence fundus angiography
	5. Hyperfluorescence of the optic disc on fluorescence fundus angiography
	Definite diagnosis:
		Variant 1: In patients presenting with A+B+C+ D(1)
		Variant 2: In patients without clinically visible exudative retinal detachment, ie, A+B+C+ D(2) + D(3) or A + B + C + D(4)
		Variant 3: In patients already treated with systemic corticosteroids or combined with other immunosuppressive agents, a history of typical appearances of variant 1 or 2, and A+B+C+ D(5)
E. Late-phase Vogt-Koyanagi-Harada disease:
	1. Signs of definite sunset glow fundus or retinal pigment epithelium clumping/migration
	2. Signs of bilateral recurrent granulomatous anterior uveitis
	3. Signs of Dalen-Fuchs nodules or multifocal chorioretinal atrophy
	4. Window defects/moth-eaten fluorescence on fluorescence fundus angiography
	5. Previous history of characteristic findings corresponding to diagnosis of early-phase Vogt-Koyanagi-Harada disease
	Definite diagnosis:
		Variant 1: In patients presenting with A+B+C+ E(1) + E(2)
		Variant 2: In patients without sunset glow fundus or visible pigment alternations due to early and appropriate treatment, ie, A+B+C+ E(2) + E(3) or A+B+C+ E(2) + E(4)
		Variant 3: In patients with significant media opacity, ie, A+B+C+ E(2) + E(5)

Criteria are evolving to include modern ophthalmic imaging findings. Indocyanine green angiography is a diagnostic imaging procedure that examines blood flow through the choroid. The fluorescent molecule indocyanine green is infused intravenously, and a series of fluorescent photographs are taken with a specialized fundus camera. Fluorescein angiography is a technique similar to indocyanine green angiography but evaluates the retinal circulation in addition to the choroid. Optical coherence tomography is a noninvasive imaging technique used to generate a cross-section of the retina and choroid.

In 2021, the Standardization of Uveitis Nomenclature (SUN) Working Group published its classification criteria of early and late-stage Vogt-Koyanagi-Harada disease, which utilized machine learning to determine a set of classification criteria that minimized misclassification of Vogt-Koyanagi-Harada disease with other forms of panuveitis (53). Over 1000 cases of panuveitis were evaluated, including 156 cases of early-stage Vogt-Koyanagi-Harada disease and 103 cases of late-stage Vogt-Koyanagi-Harada disease. The 95% confidence interval for overall accuracy was between 89.0% and 96.8%.

Table 3. Classification Criteria for Early-Stage Vogt-Koyanagi-Harada Disease

Criteria Diagnosis requires 1 or 2 AND 3
	1. Evidence of Harada disease
		a. Serous (exudative) retinal detachment AND (b) and/or (c)
		b. Multiloculated appearance on fluorescein angiogram OR
		c. Septae on optical coherence tomogram
OR
	2. Panuveitis^a with two or more of the following neurologic symptoms or signs^b
		a. Headache OR
		b. Tinnitus OR
		c. Dysacusis OR
		d. Meningismus OR
		e. Cerebrospinal fluid pleocytosis
AND
	3. No history of penetrating ocular trauma or vitreoretinal surgery prior to disease onset
Exclusions
	1. Positive serology for syphilis using a treponemal test
	2. Evidence for sarcoidosis (either bilateral hilar adenopathy on chest imaging or tissue biopsy demonstrating noncaseating granulomata)
^a Uveitis should have evidence of choroidal involvement on clinical examination, fluorescein angiography, indocyanine green angiography, or optical coherence tomography, including enhanced depth imaging of the choroid.
^b Onset of neurologic symptoms and signs and onset of the uveitis should occur within 4 weeks of each other.
(53)

Table 4. Classification Criteria for Late-Stage Vogt-Koyanagi-Harada Disease

Criteria
	1. History of early-stage Vogt-Koyanagi-Harada disease
AND 2 and/or 3
	2. Sunset glow fundus
OR
	3. Uveitis* AND one or more of the following cutaneous findings
		a. Vitiligo OR
		b. Poliosis OR
		c. Alopecia
Exclusions
	1. Positive serology for syphilis using a treponemal test
	2. Evidence for sarcoidosis (either bilateral hilar adenopathy on chest imaging or tissue biopsy demonstrating noncaseating granulomata)
* Uveitis may be (1) chronic anterior uveitis; (2) anterior and intermediate uveitis; or (3) panuveitis with multifocal choroiditis (“Dalen Fuchs–like nodules”)
(53)

Ophthalmic ancillary testing. During the acute uveitic stage, indocyanine green angiography demonstrates multifocal areas of delayed choroidal filling. In the late stages, peripapillary and multifocal choroidal pinpoint leakage can be seen. Indocyanine green may pool late in the areas of serous retinal detachment. Features on pre-treatment ICG angiography may also provide prognostic value (179).

Fluorescein angiography demonstrates similar punctate hyperfluorescence in the choroid and retinal pigment epithelium, with progressive staining in areas of active choroiditis in the later phase of the angiogram. Dye can similarly accumulate in the areas of serous retinal detachments. This pattern of hyperfluorescence is said to give a “moth-eaten” appearance. Optic nerve head leakage is found in 70% of cases (112).

Due to differences in protein binding and wavelengths used, there are differences between indocyanine green angiography and fluorescein angiography leakage patterns. Indocyanine green angiography is advantageous for evaluating the choroid and retinal pigment epithelium, with less interference from the retinal pigment epithelium (51).

Melanin accumulation may be seen with near-infrared photography with corresponding hyper-reflectivity on optical coherence tomography. These lesions may resolve with treatment (108). Spectral domain optical coherence tomography (sdOCT) is another noninvasive diagnostic modality used to assess the retina, retinal pigment epithelium, and choroid. This technique can be used to monitor retinal and choroidal thickness, as well as the extent of subretinal fluid. It is routinely performed in the office, and acquisition is rapid, thus, making it one of the most commonly used imaging modalities to monitor disease activity (69; 07; 68) and predict recurrence (56).

Swept-source and enhanced depth imaging optical coherence tomography have also been used to evaluate increased choroidal thickness in acute Vogt-Koyanagi-Harada syndrome. Swept-source optical coherence tomography has better resolution for the choroid than enhanced depth imaging optical coherence tomography and can be used to follow resolution of inflammation after treatment with steroids (145). Fibrin membranous structures on OCT were associated with younger age, greater disease severity, and cumulative steroid dose but did not affect final visual outcome (113). Optical density of subretinal fluid has not been shown to be helpful in differentiating Vogt-Koyanagi-Harada syndrome from other causes of serous retinal detachment (37).

Optical coherence tomography angiography is a noninvasive imaging technique that provides an angiogram of the retinal and choroidal vasculature without the need for intravascular fluorophores. Optical coherence tomography angiography has shown multiple dark foci at the level of the choriocapillaris corresponding with hypocyanescence on indocyanine green angiography, indicating hypoperfusion and ischemia. Microvascular density is significantly decreased in eyes with sunset glow fundus (38). Flow defects, as well as vascular density, have been shown to worsen in acute disease (199; 32) and improve with glucocorticoid treatment (145; 58). Further, optical coherence tomography angiography has demonstrated changes in choroidal thickness and blood flow in active and remitting disease (40). It has also demonstrated flow voids preceding clinically relapsing disease (63). Thus, optical coherence tomography angiography can be used to detect subclinical disease activity as well as monitor response to treatment. Persistent flow voids in the convalescent phase were associated with worse final visual acuity (19). The presence of optic nerve swelling is associated with lower retinal arteriolar blood flow and oxygen saturation (04), as well as lower peripapillary vessel densities (71).

Ultrasound biomicroscopy may show ciliochoroidal detachment (20%) and unclear ciliary processes (15%), which are characteristic in the uveitic phase. These changes improve with treatment but may be observed in recurrent uveitis (136).

Adaptive optics scanning laser ophthalmoscopy, an emerging technology, may be a useful indicator measuring photoreceptor density during active disease and recovery (144). Laser speckle flowgraphy (02; 04) and retinal oximetry has also been used to evaluate choroidal perfusion in Vogt-Koyanagi-Harada syndrome (03).

Neurologic ancillary testing. Lumbar puncture yields diagnostically useful information in the form of lymphocytic pleocytosis in a high percentage of patients, if fluid is sampled within the first 8 weeks. There may be a lag in the development of pleocytosis, as the percentage of patients with this finding rises from 80% in the first week of symptoms to 97% by the third week (171; 112). Other authors questioned the necessity of CSF examination and found that fluorescein angiography along with clinical examination were diagnostic even in patients without cerebrospinal fluid pleocytosis (181).

Though MRI is often obtained for workup of neurologic symptoms, findings are often nonspecific related to leptomeningeal inflammation. Le described a case of Vogt-Koyanagi-Harada syndrome presenting with bilateral optic nerve swelling and leptomeningeal enhancement (92). Ikeda and Tsukuguchi report a case of Vogt-Koyanagi-Harada syndrome with multiple hyperintense signal abnormalities in the cerebral white matter. One patient had high signal abnormalities in the periventricular cerebral white matter (59).

MRI may show choroidal thickening, indicating a concurrent ocular process (73; 112; 143). Theta-range slowing of the EEG is often present, but this is so nonspecific as to be relatively unhelpful in establishing the diagnosis of Vogt-Koyanagi-Harada syndrome.

Other ancillary testing. In small series, the measurement of individual cell populations may be useful in differentiating Vogt-Koyanagi-Harada syndrome from other uveitic syndromes (76) and measuring response to treatment.

Management

High-dose systemic corticosteroid treatment is recommended during the uveitic stage, with slow dosage tapering over the subsequent 3 to 6 months. Treatment is generally monitored by ophthalmologic parameters, and patients should be under the care of an ophthalmologist for this. High-dose corticosteroid treatment can induce central serous choroidopathy in patients with Vogt-Koyanagi-Harada as with other forms of chronic uveitis and this must be considered as possibly causative if a patient has worsening of visual acuity with treatment (162).

The neurologic problems are generally limited to the prodromal and early uveitic stages. Specific management of these problems is seldom an issue. Recurrences during corticosteroid tapering may become refractory to treatment and require the use of cytotoxic agents such as cyclophosphamide, chlorambucil, or azathioprine, or cytostatic agents such as cyclosporine (112).

Case reports and case series have shown stable control achieved with mycophenolate mofetil (05), rituximab (34), infliximab (209), tofacitinib (35), and adalimumab (168; 90; 176; 164). Small series have demonstrated improved visual acuity outcomes in patients treated early with immunomodulatory therapy (139). Large reviews suggest that steroidal and nonsteroidal dual therapy given at onset is better than corticosteroid monotherapy alone (55; 138; 196). Biologics have shown promise in achieving control in refractory and recurrent disease (21; 197; 164).

In a clinical trial of 110 patients, initial treatment with cyclosporine showed similar efficacy compared to adalimumab when combined with a low-dose oral corticosteroid (207).

In case reports and one small prospective study, intravitreal dexamethasone implant (24; 26; 36) or intravitreal fluocinolone acetonide implant combined with intravitreal methotrexate (140) has shown efficacy. In a small series, suprachoroidal steroid injections were shown to be an effective adjunct to oral steroid therapy in treating serious retinal detachment (174). These local therapies may be a safe alternative for patients who develop morbidity or adverse events with systemic treatment.

Vitrectomy to drain subretinal fluid has been described. However, in a small case series, three of five eyes with Vogt-Koyanagi-Harada syndrome that underwent vitrectomy had recurrence of serous retinal detachment that did not respond to medical therapy and required repeat surgery (153).

Outcomes

A study of 97 consecutive patients presenting in Riyadh, Saudi Arabia, included 13 children and 84 adults (173). Sixty-one percent (eight patients) of those younger than 14 years of age (children) required cataract surgery, as compared with 17% (14 patients) of the adults. Sixty-one percent of the children had final visual acuity equal to or worse than 20/200, whereas only 26% of adults had that severe visual consequence. Chronic recurrent disease is associated with worse outcomes in children (08).

Of 98 patients with Vogt-Koyanagi-Harada syndrome seen at the Aravind Eye Hospital in Madurai, India, between 1993 and 1995, three were children (under 16 years of age), and all required cataract surgery (152). Visual outcome was good, despite the eventual development of retinal pigment epithelial atrophy in two children and glaucoma in one child. The presence of posterior synechiae at diagnosis is associated with an increased risk of recurrent anterior uveitis (98). Patients with Vogt-Koyanagi-Harada syndrome who develop a bullous retinal detachment have an eight times higher risk of developing subretinal fibrosis (46). Late presentation, recurrent inflammation, and iris and angle scarring were associated with greater development of secondary glaucoma (10; 202). Patients with bacillary layer detachment had more severe disease in the acute phase and a higher rate of recurrence within the first 6 months (89).

Small series have demonstrated improved visual acuity outcomes in patients treated early with immunomodulatory therapy (139; 99; 39). However, some have observed increased adverse events in patients who start immunomodulatory therapy immediately and have proposed early initiation of immunomodulation based on stratified risk (72). Initiation of treatment preceding anterior segment inflammation (a late presentation) was associated with fewer long-term complications (04). More aggressive treatment with intravenous methylprednisolone compared to conventional dose oral corticosteroids showed fewer recurrences and better long-term visual outcomes (109). This may be a pulse of intravenous corticosteroids followed by an oral taper (43). Finally, it has also been shown that patients whose initial corticosteroid treatment was continued for 6 months or longer have significantly fewer late recurrences of ocular inflammation than patients initially treated for less than 6 months (91).

Patients on high-dose corticosteroid or immunomodulatory therapy are at increased risk of opportunistic infections. Some of these infections may also manifest as posterior uveitis, complicating the management and clinical picture. Cases of tuberculosis uveitis and cytomegalovirus retinitis during therapy for Vogt-Koyanagi-Harada syndrome have been described (79; 14). Development of COVID-19 has also been described during immunosuppressive therapy (127), although some authors suggest that the antiviral properties of cyclosporine as a treatment agent may reduce this risk (123).

Reversal of iris depigmentation with treatment has been described (180).

Control of uveitis, better vision, and treatment-free survival were associated with higher quality of life scores (167).

Media

References

01: Abdelnabi M, Rimu A, Siddiqui S, Mora B, Guerin C. Ocular syphilis mimicking Vogt-Koyanagi-Harada syndrome: a diagnostic dilemma. Proc (Bayl Univ Med Cent) 2023;36(3):380-2. PMID 37101906
02: Abe S, Nakamura T, Okumura E, Oiwake T, Okada AA, Hayashi A. Long-term changes of choroidal blood flow velocity in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 2022;260(6):1933-9. PMID 34982220
03: Abu El-Asrar AM, AlBloushi AF, Gikandi PW, Alzubaidi A, Stefánsson E. Changes in ocular blood flow and retinal oxygen metabolism during immunosuppressive therapy for initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2022;100(6):707-12. PMID 35235253
04: Abu El-Asrar AM, Al Rashed FA, AlBloushi AF, et al. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: prevention of late autoimmune complications by early intervention. Acta Ophthalmol 2023;101(2):e236-45. PMID 36128841
05: Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harads disease. Acta Ophthalmol 2017;95(1):85-90. PMID 27535102
06: Accorinti M, Saturno MC, Manni P. Vogt-Koyanagi-Harada relapse after COVID-19 vaccination. Ocul Immunol Inflamm 2022;30(5):1228-33. PMID 35201950
07: Agarwal M, Radosavljevic A, Patnaik G, Rishi E, Pichi F. Diagnostic value of optical coherence tomography in the early diagnosis of macular complications in chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2022;30(4):801-8. PMID 33136534
08: AlBloushi AF, AlEnezi SH, Al Owaifeer AM, Al-Hadlaq OS, Gikandi PW, Abu El-Asrar AM. Long-term outcomes of uveitis associated with Vogt-Koyanagi-Harada disease in the pediatric age group. Ocul Immunol Inflamm 2022;30(7-8):1669-77. PMID 34184966
09: Alromaih AZ, Almater AI, Albloushi AF, Alkheraiji NF, Abu El-Asrar AM. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy. Int Ophthalmol 2023;43(1):185-95. PMID 35945413
10: Alvarez-Guzman C, Hartleben-Matkin C, Ruiz-Lozano RE, Rodriguez-Garcia A, Quiroga-Garza ME, Valdez-Garcia JE. Risk factors for secondary glaucoma in patients with Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect 2022a;12(1):22. PMID 35816207
11: Alvarez-Guzman C, Valdez-Garcia JE, Ruiz-Lozano RE, et al. High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease. Int Ophthalmol 2022b;42(12):3913-21. PMID 35789316
12: Amagai R, Fujimura T, Yamazaki E, et al. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04. J Dermatol 2024;51(6):854-7. PMID 38111371
13: Amaral C, Rodriguez E, Barquet V, et al. Seasonal patterns of Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2023;31(2):362-6. PMID 35133938
14: Anderson EW, El Khoury L, Schwartzman-Morris JS, Jonisch J, Goldberg NR. Tuberculous choroiditis in patient with Vogt-Koyanagi-Harada disease. Retin Cases Brief Rep 2021;15(3):302-5. PMID 30074567
15: Angioi K, Bodaghi B, Kaminsky P, Mokhtari K, Lubetzki C, LeHoang P. Intravascular lymphoma mimicking a Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2011;19(2):132-4. PMID 21428755
16: Anquetil C, Salem JE, Lebrun-Vignes B, et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. J Autoimmun 2020;111:102454. PMID 32303423
17: Arriola-Villalobos P, Moll-Udina A, Carrasco-López-Brea M, et al. Vogt-Koyanagi-Harada disease in Spain. Eur J Ophthalmol 2022;32(3):1547-54. PMID 34269103
18: Babel J. Syndrome de Vogt-Koyanagi (Uveite bilaterale, poliosis, alopecie, vitiligo et dysacousie). Schweiz Med Wochenschr 1932;44:1136-40.
19: Ben Aoun S, Ksiaa I, Nefzi D, et al. SS OCT and OCT-A findings in convalescent inactive Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2024;32(4):407-14. PMID 37948509
20: Biswas J, Narain S, Das D, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol 1996;20(4):223-8. PMID 9112191
21: Bolletta E, Gozzi F, Mastrofilippo V, et al. Efficacy of rituximab treatment in Vogt-Koyanagi-Harada disease poorly controlled by traditional immunosuppressive treatment. Ocul Immunol Inflamm 2022;30(6):1303-8. PMID 33793383
22: Brambati M, Giuffrè C, Marchese A, Bandello F, Modorati GM, Miserocchi E. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. Eur J Ophthalmol 2022;32(1):NP109-13. PMID 32998540
23: Bruno MG, McPherson SD. Harada's disease. Am J Ophthalmol 1949;32:513-22. PMID 18114396
24: Campos Polo R, García Guisado D, Rubio Sánchez C, Márquez Ivacevich NT. Usefulness of intravitreal dexamethasone implant in the management of «Vogt-Koyanagi-Harada-like syndrome» secondary to map kinase pathway inhibition. Arch Soc Esp Oftalmol (Engl Ed) 2020;95(10):501-6. PMID 32593600
25: Chan CC, Palestine AG, Nussenblatt RB. Antiretinal auto-antibodies in Vogt-Koyanagi-Harada syndrome, Behcet's disease, and sympathetic ophthalmia. Ophthalmology 1985;92:1025-8. PMID 3900848
26: Chen PL, Chen SN. Efficacy of intravitreal dexamethasone implant in patients with Vogt-Koyanagi-Harada disease and bilateral panuveitis: two case reports. Medicine (Baltimore) 2021;100(40):e27394. PMID 34622843
27: Chen Z, Zhong Z, Zhang W, Su G, Yang P. Integrated analysis of key pathways and drug targets associated with Vogt-Koyanagi-Harada disease. Front Immunol 2020;11:587443. PMID 33384687
28: Cowper AR. Harada's disease and Vogt-Koyanagi syndrome. Uveoencephalitis. AMA Arch Ophthalmol 1951;45:367-76. PMID 14818491
29: Czichos C, Wawrzynów B, Chamalis C, von Jagow B. Bilateral nivolumab-associated Vogt-Koyanagi-Harada-like uveitis in a patient with metastatic renal cell carcinoma. [Article in German] Klin Monbl Augenheilkd 2021;238(6):711-4. PMID 33395707
30: Dallinga MG, Bolhuis K, Bins A, de Hoog J. Bilateral diffuse uveal melanocytic proliferation mistaken for nivolumab-induced VKH-like syndrome. Retin Cases Brief Rep 2024;18(3):332-6. PMID 36728009
31: De Domingo B, López M, Lopez-Valladares M, Ortegon-Aguilar E, Sopeña-Perez-Argüelles B, Gonzalez F. Vogt-Koyanagi-Harada disease exacerbation associated with COVID-19 vaccine. Cells 2022;11(6):1012. PMID 35326462
32: Ding X, Shu Q, Bai X, Chang Q, Xu G, Chen L. The role of widefield optical coherence tomography angiography in the diagnosis and management of acute Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2024;32(4):391-401. PMID 36856749
33: Dogan B, Erol MK, Cengiz A. Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis. Springerplus 2016;5:603. PMID 27247899
34: Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect 2011;1(4):177-80. PMID 21744181
35: Dutta Majumder P, Shah A, Kaushik V. Tofacitinib in Vogt-Koyanagi-Harada disease. Indian J Ophthalmol 2020;68(9):1938-9. PMID 32823421
36: Elhamaky TR. Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis. Indian J Ophthalmol 2022;70(7):2465-70. PMID 35791135
37: Engin CD, Kayabasi M, Koksaldi S, Ipek SC, Saatci AO. Does subretinal fluid optical density ratio differ among the eyes with acute central serous chorioretinopathy, Vogt Koyanagi Harada disease and choroidal hemangioma: a cross-sectional study. Photodiagnosis Photodyn Ther 2023;42:103634. PMID 37244453
38: Fan S, Lin D, Hu J, Cao J, et al. Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography. Eye (Lond) 2021;35(7):1993-8. PMID 33024324
39: Fauquier A, Barba T, Hot A, et al. Impact of initial management on disease evolution in Vogt-Koyanagi-Harada syndrome: a retrospective cohort of 50 patients. Ocul Immunol Inflamm 2024;32(4):402-6. PMID 37141529
40: Fayed AE, Gerges TK. Optical coherence tomography angiography reveals paradoxically decreasing choroidal thickness and increasing blood flow in remitting Vogt-Koyanagi-Harada syndrome. Retina 2022;42(9):1788-95. PMID 35552322
41: Federman DG, Kravetz JD, Ruser CB, Judson PH, Kirsner RS. Vogt-Koyanagi-Harada syndrome and ulcerative colitis. South Med J 2004;97(2):169-71. PMID 14982267
42: Fishman RA. Cerebrospinal fluid in diseases of the nervous system. 2nd ed. Philadelphia: WB Saunders, 1992:291.
43: Fushitsu R, Ishibazawa A, Murono M, Kinouchi R. Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy. Int Ophthalmol 2023;43(2):431-40. PMID 35869402
44: Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 2020;12(7):439-44. PMID 32308086
45: Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2001;42(9):2004-9. PMID 11481264
46: Golzarri MF, Cheja-Kalb R, Concha-Del-Río LE, Gonzalez-Salinas R, Arellanes-García L. Risk factors for subretinal fibrosis in patients with Vogt Koyanagi Harada syndrome. Ocul Immunol Inflamm 2020;1-5. PMID 33021860
47: Gu S, Liu Y, Song Z, Zi X, Deng H. Acute myelitis in a patient with vogt-koyanagi-harada disease: case report and review of the literature. J Clin Neurol 2013;9(1):61-4. PMID 23346163
48: Guo K, Li B, Yang F, Zhang M, Zhao G, Zhang X. Different MicroRNA profiles in peripheral blood mononuclear cells from patients with initial-onset and recurrent Vogt-Koyanagi-Harada disease. Mol Biol Rep 2022;49(12):11421-31. PMID 35988105
49: Han HJ, Kim HY, Park JH, Lee EJ, Kim do G, Shin DI. Magnetic resonance imaging of pachymeningeal enhancement in Vogt-Koyanagi-Harada disease. Neurol Sci 2010;31(6):785-8. PMID 20198496
50: Harada E. Beitrag zur klinischen Kenntnis von Michteitriger Choroiditis (choroiditis diffusa acta). Acta Soc Ophthalmol Jpn 1926;30:356-78.
51: Harada T, Kanbara Y, Takeuchi T, Niwa T, Majima T. Exploration of Vogt-Koyanagi-Harada syndrome by infrared choroidal angiography with indocyanine green. Eur J Ophthalmol 1997;7(2):163-70. PMID 9243221
52: Hassanpoor N, Niyousha MR. Acute lymphoblastic leukemia presenting as acute Vogt-Koyanagi-Harada syndrome. Case Rep Ophthalmol 2020;11(2):481-5. PMID 32999679
53: Heiligenhaus A, Rothaus K, Pleyer U. Entwicklung von Klassifikationskriterien für Uveitiden von der Standardization of Uveitis Nomenclature (SUN) Working Group [Development of classification criteria for uveitis by the standardization of uveitis nomenclature (SUN) working group]. Ophthalmologe 2021;118(9):913-8. PMID 34459962
54: Herbort CP, Mochizuki M. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Opththalmol 2007;27(2-3):67-79. PMID 17468832
55: Herbort CP, Tugal-Tutkun I, Khairallah M, Abu El Asrar AM, Pavésio CE, Soheilian M. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area. Int Ophthalmol 2020;40(9):2423-33. PMID 32418076
56: Hirota Y, Muraoka Y, Kogo T, et al. Association of retinal pigment epithelium reflectivity on optical coherence tomography with recurrence of Vogt-Koyanagi-Harada disease: a retrospective observational study. Clin Ophthalmol 2023;17:2071-9. PMID 37496848
57: Hu Y, Hu Y, Xiao Y, et al. Genetic landscape and autoimmunity of monocytes in developing Vogt-Koyanagi-Harada disease. Proc Natl Acad Sci U S A 2020;117(41):25712-21. PMID 32989127
58: Hua R, Wang N, Liu L, Ning H. Improvement of vascular density of macular capillaries in acute Vogt-Koyanagi-Harada disease after glucocorticoid therapy. Clin Exp Ophthalmol 2021;49(5):524-7. PMID 33882181
59: Ibanez HE, Grand MG, Meredith TA, Wippold FJ. Magnetic resonance imaging findings in Vogt-Koyanagi-Harada syndrome. Retina 1994;14:164-8. PMID 8036326
60: Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease. Curr Eye Res 2001;22(4):312-8. PMID 11462171
61: Ingolotti M, Schlaen BA, Roig Melo-Granados EA, Ruiz García H, Aguilera Partida JA. Azathioprine during the first trimester of pregnancy in a patient with Vogt-Koyanagi-Harada disease: a multimodal imaging follow-up study. Am J Case Rep 2019;20:300-5. PMID 30842390
62: Inomata H, Kato M. Vogt-Koyanagi-Harada disease. In: McKendall RR, editor. Viral disease. Amsterdam: Elsevier, 1989:611-26.
63: Interlandi E, Pellegrini F, Papayannis A, Latanza L, Pece A, Pavesio C. Predictive role of swept-source OCT angiography in relapsing Vogt-Koyanagi Harada disease. Retin Cases Brief Rep 2023;17(4):414-8. PMID 35880955
64: Islam SM, Numaga J, Fujino Y, et al. HLA class 2 genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994a;35:3890-6. PMID 7906684
65: Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994b;35:752-6. PMID 7906684
66: Islam M, Tabbara K. Causes of uveitis at The Eye Center in Saudi Arabia: A retrospective review. Ophthalmic Epidemiol 2002;9(4):239-49. PMID 12187422
67: Jabs DA, Hanneken AM, Schachat AP, Fine SL. Choroidopathy in systemic lupus erythematosus. Arch Ophthalmol 1988;106:230-4. PMID 3341980
68: Jacob N, Tyagi M, Chhablani J, et al. Retinal pigment epithelial characteristics in acute and resolved Vogt-Koyanagi-Harada disease. J Clin Med 2023;12(6):2368. PMID 36983367
69: Jaisankar D, Raman R, Sharma HR, et al. Choroidal and retinal anatomical responses following systemic corticosteroid therapy in Vogt-Koyanagi-Harada disease using swept-source optical coherence tomography. Ocul Immunol Inflamm 2019;27(2):235-43. PMID 28700251
70: Ji H, Zhang N, Zhu M, Dong J, Jiang Z. Elevated serum immunoglobulin E levels are associated with the severity of newly diagnosed, acute Vogt-Koyanagi-Harada disease. Curr Eye Res 2022;47(1):102-6. PMID 34264155
71: Jiang Z, Ji H, Zhang N, Huang L, Zhou M, Dong J. Changes of peripapillary capillary density in patients with Vogt-Koyanagi-Harada disease evaluated by optical coherence tomography angiography. J Ophthalmol 2023;2023:1271070. PMID 37102070
72: Jin K, Liang A, Song H, et al. A novel risk stratification-based immunomodulatory treatment strategy for Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2024. PMID 38369223
73: Johnston CA, Teitelbaum CS. Magnetic resonance imaging in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1990;108:783-4. PMID 2350278
74: Joo CW, Kim YK, Park SP. Vogt-Koyanagi-Harada disease following mRNA-1273 (Moderna) COVID-19 vaccination. Ocul Immunol Inflamm 2022;30(5):1250-4. PMID 35404752
75: Kahn M, Pepose JS, Green WR, Miller J, Foos RY. Immunocytologic findings in a case of Vogt-Koyanagi-Harada syndrome. Ophthalmology 1993;100:1191-8. PMID 8341501
76: Kang H, Sun H, Yang Y, et al. Autoimmune uveitis in Behçet's disease and Vogt-Koyanagi-Harada disease differ in tissue immune infiltration and T cell clonality. Clin Transl Immunology 2023;12(9):e1461. PMID 37720629
77: Kaya P, İnanç Tekin M, Özdal PÇ. Predictive factors for the prognosis of Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2023;31(8):1687-93. PMID 36628436
78: Khochtali S, Ksiaa I, Megzari K, Khairallah M. Retinal pigment epithelium detachment in acute Vogt-Koyanagi-Harada disease: an unusual finding at presentation. Ocul Immunol Inflamm 2019;27(4):591-4. PMID 29513616
79: Khochtali S, Mahjoub A, Dridi T, Ksiaa I, Abroug N, Khairallah M. Cytomegalovirus retinitis following corticosteroid overdose for Vogt-Koyanagi-Harada disease. Indian J Ophthalmol 2020;68(9):2012-14. PMID 32823462
80: Kim LA, Khurana RN, Parikh JG, Rao NA. Melanin-laden macrophages in the CSF to diagnose Vogt-Koyanagi-Harada simulating ocular syphilis. Ocul Immunol Inflamm 2008;16(1):59-61. PMID 18379946
81: Kim SY, Kang MS, Kwon HJ. Bilateral panuveitis mimicking Vogt-Koyanagi-Harada disease following the first dose of ChAdOx1 nCoV-19 vaccine. Ocul Immunol Inflamm 2022;30(5):1218-21. PMID 35113750
82: Kimura H, Ohashi N, Aso S, Watanabe Y. Clinical study of the role of melanocytes in the inner ear of patients with Harada's disease. ORL J Otorhinolaryngol Relat Spec 1996;58(4):233-7. PMID 8883112
83: Kirmani MH, Thomas EL, Rao NA, Laborde RP. Intraocular reticulum cell sarcoma: diagnosis by choroidal biopsy. Br J Ophthalmol 1987;71:748-52. PMID 3314978
84: Kissel P, Hartemann P, Schmitt J. Les uveo-nevraxites virales ou presumee telles. Rev Neurol (Paris) 1963;108:275-80.
85: Kobayashi H, Kokubo T, Takahashi M, et al. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998;47:398-403. PMID 9510558
86: Koong LR, Chee WK, Toh ZH, Ng XL, Agrawal R, Ho SL. Vogt-Koyanagi-Harada disease associated with COVID-19 mRNA vaccine. Ocul Immunol Inflamm 2021;29(6):1212-15. PMID 34505819
87: Kosma KK, Kararizou E, Markou I, et al. Headache as a first manifestation of Vogt-Koyanagi-Harada disease. Med Princ Pract 2008;17(3):253-4. PMID 18408397
88: Koyanagi Y. Dysakusis, Alopecia und Poliosis bei schwerer uveitis nicht traumatischen Ursprungs. Klin Monatsbl Augenheilkd 1929;82:194-211.
89: Kwak JJ, Lee J, Byeon SH. Clinical features and prognostic value of bacillary layer detachment in acute Vogt-Koyanagi-Harada disease. Retina 2023;43(10):1700-7. PMID 37315551
90: Kwon HY, Woo SJ. A case of recurrent Vogt-Koyanagi-Harada disease successfully treated with adalimumab in young female adult patient. Korean J Ophthalmol 2020;34(1):92-3. PMID 32037756
91: Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye 2009;23(3):543-8. PMID 18369377
92: Le TA, Simon S, Gilhotra J, Hissaria P. Vogt-Koyanagi-Harada syndrome presenting with bilateral optic disc swelling and leptomeningeal enhancement. BMJ Case Rep 2019;12(5):e229719. PMID 31118177
93: Lee KE, Kim YJ. Bilateral multiple retinal detachments associated with diffuse large B-cell lymphoma: masquerading as Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2023;31(1):7-10. PMID 34520312
94: Li M, Liu M, Wang X, Wei H, Jin S, Liu X. Comparison of intestinal microbes and metabolites in active VKH versus acute anterior uveitis associated with ankylosing spondylitis. Br J Ophthalmol 2023a:bjo-2023-324125. PMID 37821210
95: Li M, Yang L, Cao J, Liu T, Liu X. Enriched and decreased intestinal microbes in active VKH patients. Invest Ophthalmol Vis Sci 2022;63(2):21. PMID 35142786
96: Li W, Tan J, He S, et al. iPSC-based model of Vogt-Koyanagi-Harada disease for phenotype recapitulation and drug screening. Clin Immunol 2023b;246:109205. PMID 36509389
97: Li X, Wang G, Wang X, et al. OR11H1 missense variant confers the susceptibility to Vogt-Koyanagi-Harada disease by mediating Gadd45g expression. Adv Sci (Weinh) 2024;11(11):e2306563. PMID 38168905
98: Lim YJ, Byon I, Kim HW, Park SW, Kwon HJ, Kim E. Incidence and risk factors of recurrent anterior uveitis in initial acute-onset Vogt-Koyanagi-Harada disease. Korean J Ophthalmol 2023;37(4):299-306. PMID 37400085
99: Lin Oo EE, Chee SP, Wong KKY, Htoon HM. Vogt-Koyanagi-Harada disease managed with immunomodulatory therapy within 3 months of disease onset. Am J Ophthalmol 2020;220:37-44. PMID 32738228
100: Lin YC, Lo KJ, Chen SJ, Hwang DK. Ocular syphilis mimicking Vogt-Koyanagi-Harada disease. Taiwan J Ophthalmol 2019;9(4):271-5. PMID 31942434
101: Liu L, Chi XY, Zhu YL, Jiao SX. The novel allele, HLA-A*11:264, was identified in a Chinese individual by sequence-based typing. HLA 2018;91(6):533-4. PMID 29504719
102: Liu X, Meng J, Liao X, et al. A de novo missense mutation in MPP2 confers an increased risk of Vogt-Koyanagi-Harada disease as shown by trio-based whole-exome sequencing. Cell Mol Immunol 2023;20(11):1379-92. PMID 37828081
103: Lohman BD, Gustafson CA, McKinney AM, Sarikaya B, Silbert SC. MR Imaging of Vogt-Koyanagi-Harada Syndrome with Leptomeningeal Enhancement. AJNR Am J Neuroradiol 2011;32(9):E169-71. PMID 21051514
104: Maehira M, Oshiro A, Imanaga N, Yamauchi Y, Koizumi H. Vogt-Koyanagi-Harada disease in a patient with extreme anisometropia. Am J Ophthalmol Case Rep 2023;32:101929. PMID 37771387
105: Mann ES, Katz B. The uveo-meningeal syndromes. In: Katz B, editor. Neuro-ophthalmology in systemic disease. Philadelphia: WB Saunders, 1992:580-1.
106: Manor RS. Vogt-Koyanagi-Harada syndrome. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: Elsevier/North-Holland, 1978:513-44.
107: McClellan KA, MacDonald M, Hersey P, Billson FA. Vogt-Koyanagi-Harada syndrome--isolation of cloned T-cells with specificity for melanocytes and melanoma cells. Aust N Z J Ophthalmol 1989;17:347-52. PMID 2624724
108: Miura M, Makita S, Azuma S, et al. Evaluation of retinal pigment epithelium layer change in Vogt-Koyanagi-Harada disease with multicontrast optical coherence tomography. Invest Ophthalmol Vis Sci 2019;60(10):3352-62. PMID 31917451
109: Miyanaga M, Kawaguchi T, Shimizu K, Miyata K, Mochizuki M. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007;27(2-3):183-8. PMID 17476572
110: Miyata N, Sugita M, Nakamura S, et al. Treatment of Vogt-Koyanagi-Harada's disease during pregnancy. Jpn J Ophthalmol 2001;45(2):177-80. PMID 11313051
111: Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2000;44(3):296-301. PMID 10913650
112: Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-92. PMID 7725227
113: Motegi S, Nagura K, Yoneda K, et al. Clinical relevance of fibrin membranous structures in the intra-photoreceptor outer segment separation on spectral domain optical coherence tomography (SD-OCT) in initial-onset acute Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2023;101(3):e286-93. PMID 36217824
114: Moussa K, Begaj T, Ma K, Barrantes PC, Eliott D, Sobrin L. Systemic lymphoma masquerading as Vogt-Koyanagi-Harada syndrome: report of a case with multimodal imaging and histopathology. Am J Ophthalmol Case Rep 2022;27:101643. PMID 35800404
115: Murakami S, Inaba Y, Mochizuki M, Nakajima A, Urayama A. A nationwide survey on the occurrence of Vogt-Koyanagi-Harada disease in Japan. Jpn J Ophthalmol 1994;38:208-13. PMID 7967215
116: Murtaza F, Pereira A, Mandelcorn MS, Kaplan AJ. Vogt-Koyanagi-Harada disease following influenza vaccination. Am J Ophthalmol Case Rep 2022;26:101516. PMID 35464684
117: Muto T, Machida S. Chronological changes of the anterior chamber structure, axial length, and refraction in patients with Vogt-Koyanagi-Harada disease. Eur J Ophthalmol 2021;31(2):491-6. PMID 31973595
118: Muto T, Sakamoto M, Imaizumi S, Kamoi K. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study. J Int Med Res 2024;52(1):3000605231221081. PMID 38170955
119: Najman-Vainer J, Levinson RD, Graves MC, Nguyen BT, Engstrom RE Jr, Holland GN. An association between Vogt-Koyanagi-Harada disease and Guillain-Barre syndrome. Am J Ophthalmol 2001;131(5):615-9. PMID 11336936
120: Nakamura S, Nakazawa M, Yoshioka M, et al. Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1996;114(10):1184-8. PMID 8859075
121: Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2012;53(4):1917-22. PMID 22408010
122: Nakao K, Mizushima Y, Abematsu N, Goh N, Sakamoto T. Anterior ischemic optic neuropathy associated with Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 2009;247(10):1417-25. PMID 19568763
123: Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H. A COVID-19 risk reduction strategy for the treatment of acute Vogt-Koyanagi-Harada disease utilizing the antiviral potential of cyclosporine. Ocul Immunol Inflamm 2023;31(2):462-7. PMID 35267414
124: Ng CC, Alsberge JB, Qian Y, Freund KB, Cunningham ET Jr. Vogt-Koyanagi-Harada-like uveitis followed by melanoma-associated retinopathy with focal chorioretinal atrophy and choroidal neovascularization in a patient with metastatic cutaneous melanoma. Retin Cases Brief Rep 2023;17(1):18-22. PMID 33394953
125: Ng XL, Betzler BK, Testi I, et al. Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm 2021;29(6):1216-24. PMID 34559576
126: Nguyen NV, Khan F, Emig M, Yeh S. Management of atypical central serous chorioretinopathy mimicking Vogt-Koyanagi-Harada disease. J Vitreoretin Dis 2023;7(3):249-53. PMID 37188205
127: Niidome S, Usui Y, Tsubota K, Sugawara R, Goto H. COVID-19 developed during systemic steroid therapy for Vogt-Koyanagi-Harada disease: a case report. Ocul Immunol Inflamm 2023;31(6):1305-9. PMID 37084286
128: Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. [Comments.] Br J Ophthalmol 1996;80(11):1002-8. PMID 8976730
129: Norose K, Yano A, Aosai F, Segawa K. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1990;31:1210-6. PMID 2142146
130: Norose K, Yano A, Wang XC, et al. Dominance of activated T-cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994;35:33-9. PMID 8300361
131: Nussenblatt RB. Clinical studies of Vogt-Koyanagi-Harada's disease at the National Eye Institute, NIH, USA. Jpn J Ophthalmol 1988;32:330-3. PMID 3230719
132: Ohno S, Char DH, Kimura SJ, O'Connor GR. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1977;83:735-40. PMID 868972
133: Oku H, Ishikawa S. Vestibulo-ocular reflex abnormality in Vogt-Koyanagi-Harada syndrome. Br J Ophthalmol 1994;78:912-6. PMID 7819175
134: Oliveira D, Martins A, Costa L, Vaz C. Vogt-Koyanagi-Harada syndrome and polyarthritis as a rare clinical manifestation. Acta Reumatol Port 2021;46(3):281-2. PMID 34663777
135: Otani S, Sakurai T, Yamamoto K, et al. Frequent immune response to a melanocyte-specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2006;90(6):773-7. PMID 16481377
136: Pachon-Suarez DI, Mayorquín Ruiz M, Concha-Del-Río LE, Cheja-Kalb R, Moragrega E, Arellanes-García L. Ultrabiomicroscopic findings in acute uveitic, convalescent and chronic recurrent stage of Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2020;28(4):626-31. PMID 31314656
137: Pandey A, Balekudaru S, Venkatramani DV, George AE, Lingam V, Biswas J. Incidence and management of glaucoma in Vogt Koyanagi Harada disease. J Glaucoma 2016;25(8):674-80. PMID 26967258
138: Papasavvas I, Tugal-Tutkun I, Herbort Jr CP. Vogt-Koyanagi-Harada is a curable autoimmune disease: early diagnosis and immediate dual steroidal and non-steroidal immunosuppression are crucial prerequisites. J Curr Ophthalmol 2020;32(4):310-4. PMID 33553831
139: Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 2006;14:87-90. PMID 16597537
140: Park JG, Callaway NF, Ludwig CA, Mahajan VB. Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis. Am J Ophthalmol Case Rep 2020;19:100859. PMID 32793845
141: Pattison EM. Uveo-meningoencephalitic syndrome (Vogt-Koyanagi-Harada). Arch Neurol 1965;12:197-205. PMID 14237777
142: Perry HD, Font RL. Clinical and histopathology observations in severe Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1977;83:242-54. PMID 836666
143: Phagura RS, Bhikoo R. MRI choroidal thickening as presenting sign of Vogt-Koyanagi-Harada disease. Asia Pac J Ophthalmol (Phila) 2021;10(1):127-8. PMID 33512834
144: Pham AT, Onghanseng N, Halim MS, et al. Reflectance adaptive optics findings in a patient with Vogt-Koyanagi-Harada disease. Am J Ophthalmol Case Rep 2022;27:101660. PMID 35880207
145: Pichi F, Aggarwal K, Neri P, et al. Choroidal biomarkers. Indian J Ophthalmol 2018;66(12):1716-26. PMID 30451172
146: Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, Pirraglia MP. Vogt-Koyanagi-Harada disease and HLA type in Italian patients. Am J Ophthalmol 1996;122(6):889-91. PMID 8956647
147: Qi J, Du L, Deng J, et al. Replication of genome-wide association analysis identifies new susceptibility loci at long noncoding RNA regions for Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2019;60(14):4820-9. PMID 31747682
148: Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol 2003;136(1):91-8. PMID 12834675
149: Ramtohul P, Comet A, Gascon P, Denis D. Pigmented paravenous retinochoroidal atrophy associated with Vogt-Koyanagi-Harada disease: a case report. BMC Ophthalmol 2020;20(1):36. PMID 31996165
150: Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 2010;117(3):591-99. PMID 20036008
151: Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome after cutaneous injury. Ophthalmology 1999;106:635-8. PMID 10080227
152: Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm 1998;6:155-61. PMID 9785605
153: Ratra D, Pradhana D, Dutta Majumder P. Surgical management for treatment-resistant cases of inflammatory exudative retinal detachment: mission impossible? Indian J Ophthalmol 2023;71(6):2543-7. PMID 37322677
154: Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001a;131(5):647-52. PMID 11336942
155: Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2001b;131(5):599-606. PMID 11336934
156: Reddy AK, John FT, Justin GA, Dahr SS. Vogt-Koyanagi-Harada disease in a Native American population in Oklahoma. Int Ophthalmol 2021;41(3):915-22. PMID 33403519
157: Riddington L, Hall AJ, Tait B, Nicholson I, Varney M. Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry. Aust N Z J Ophthalmol 1996;24(2):147-9. PMID 9199747
158: Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol 1991;109:1270-4. PMID 1929956
159: Sakata VM, da Silva FT, Hirata CE, et al. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Opthalmol 2015;253(5):785-90. PMID 25592477
160: Sanchez-Vicente JL, Moruno-Rodríguez A, De Las Morenas-Iglesias J, et al. Clinical manifestations and treatment of Vogt-Koyanagi-Harada disease during pregnancy and after birth: a case report. Ocul Immunol Inflamm 2023;31(4):830-7. PMID 35404732
161: Saraceno JJF, Souza GM, Dos Santos Finamor LP, Nascimento HM, Belfort Jr R. Vogt-Koyanagi-Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int J Retina Vitreous 2021;7(1):49. PMID 34462013
162: Schalenbourg A, Leys A, De Courten C, Coutteel C, Herbort CP. Corticosteroid-induced central serous chorioretinopathy in patients with ocular inflammatory disorders. Klin Monatsbl Augenheilkd 2002;219(4):264-7. PMID 12022014
163: Semble EL, Chmelewski WL, Pisko EJ. Vasculitis. A practical approach to management. Postgrad Med 1991;90:161-70. PMID 1676510
164: Shinagawa M, Namba K, Mizuuchi K, et al. The steroid-sparing effect of adalimumab in the treatment for the recurrent phase of Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2023;31(3):501-5. PMID 35212595
165: Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB10405 and DRB10410. Br J Ophthalmol 1994a;78:223-6. PMID 7908535
166: Sood AB, O'Keefe G, Bui D, Jain N. Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 2019;27(4):524-7. PMID 29953303
167: Souto FMS, Missaka RFBG, Lavezzo MM, et al. Quality of Life (QoL) in non-acute Vogt-Koyanagi-Harada disease (VKHD) at two time points 24 months apart. Ocul Immunol Inflamm 2023. PMID 36637906
168: Su E, Oza VS, Latkany P. A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab. J Formos Med Assoc 2019;118(5):945-50. PMID 30616991
169: Su G, Du L, Yu H, et al. Epigenome-wide association study identifies Vogt-Koyanagi-Harada disease-associated DNA methylation loci in Chinese. Exp Eye Res 2023;233:109553. PMID 37394087
170: Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 1996;8(5):799-803. PMID 8671669
171: Sugiura S. Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1978;22:9-35.
172: Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 2003;10(6):467-70. PMID 14633182
173: Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand 1998;76:723-6. PMID 9881561
174: Tabl AA, Elsayed MA, Tabl MA. Suprachoroidal triamcinolone acetonide injection: a novel therapy for serous retinal detachment due to Vogt-Koyanagi Harada disease. Eur J Ophthalmol 2022;32(6):3482-8. PMID 35266801
175: Takahashi H, Takase H, Terada Y, Mochizuki M, Ohno-Matsui K. Acquired myopia in Vogt-Koyanagi-Harada disease. Int Ophthalmol 2019;39(3):521-31. PMID 29397539
176: Takayama K, Obata H, Takeuchi M. Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy. Ocul Immunol Inflamm 2020;28(3):509-12. PMID 31268769
177: Takeuchi M, Meguro A, Nakamura J, et al. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors. Sci Rep 2023;13(1):13580. PMID 37604934
178: Tieger MG, Eliott D, Cakir B, Dahrouj M. Checkpoint inhibitor-associated Vogt-Koyanagi-Harada disease presenting 3 months following discontinuation of nivolumab. Ophthalmic Surg Lasers Imaging Retina 2023;54(3):183-7. PMID 36944065
179: Tobaigy MF, Abouammoh MA, AlBloushi AF, et al. Prognostic value of pretreatment indocyanine green angiography in the acute uveitic phase of Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2024a;102(5):e679-86. PMID 38131519
180: Tobaigy MF, AlBloushi AF, Al-Dhibi HA. Reversal of peripheral iris depigmentation associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2024b;32(4):424-8. PMID 36657743
181: Tsai JH, Sukavatcharin S, Rao NA. Utility of lumbar puncture in diagnosis of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007;27(2-3):189-94. PMID 17340216
182: Urzua CA, Velasquez V, Sabat P, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2015;93(6):e475-80. PMID 25565265
183: Vogt A. Fruhzeitiges Ergrauen def Zilien und Bemerkungen uber den sogenannten plotlzichen Entritt dieser Veranderung. Klin Monatsbl Augenheilkd 1906;4:228-42.
184: Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm 2003;11(4):277-86. PMID 14704899
185: Wang Q, Wu S, Ye X, et al. Gut microbial signatures and their functions in Behcet's uveitis and Vogt-Koyanagi-Harada disease. J Autoimmun 2023;137:103055. PMID 37208257
186: Wang Y, Ju Y, Wang J, et al. Identification of immune hub genes participating in the pathogenesis and progression of Vogt-Koyanagi-Harada disease. Front Immunol 2022;13:936707. PMID 35958546
187: Weisz JM, Holland GN, Roer LN, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology 1995;102(7):1012-5. PMID 9121744
188: Wieder MS, Fleischman JA, Rashid S. Bilateral serous retinal detachments associated with burkitt lymphoma. Am J Ophthalmol Case Rep 2020;18:100654. PMID 32195444
189: Wong SS, Ng SK, Lee HM. Vogt-Koyanagi-Harada disease: extensive vitiligo with prodromal generalized erythroderma. Dermatology 1999;198:65-8. PMID 10026405
190: Wu Q, Zhong Z, Zhou C, Cao Q, Su G, Yang P. Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada disease. BMC Med Genomics 2023;16(1):113. PMID 37221558
191: Yamada K, Senju S, Shinohara T, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett 2001;78(3):161-8. PMID 11578690
192: Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res 2000;71(4):361-9. PMID 10995557
193: Yang P, Liu S, Zhong Z, et al. Comparison of clinical features and visual outcome between sympathetic ophthalmia and Vogt-Koyanagi-Harada disease in Chinese patients. Ophthalmology 2019;126(9):1297-305. PMID 30959067
194: Yang P, Sun M, Liu X, et al. Alterations of color vision and central visual field in patients with Vogt-Koyanagi-Harada syndrome. J Ophthalmic Inflamm Infect 2012;2(2):75-9. PMID 22297830
195: Yang P, Zhong Y, Du L, et al. Development and evaluation of diagnostic criteria for Vogt-Koyanagi-Harada disease. JAMA Ophthalmol 2018;136(9):1025-31. PMID 29978190
196: Yang S, Tao T, Huang Z, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy. Front Med (Lausanne) 2022a;8:799427. PMID 35096888
197: Yang S, Tao T, Li Z, et al. Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients. Ann Transl Med 2022b;10(12):699. PMID 35845536
198: Yasaka Y, Hasegawa E, Keino H, et al. A multicenter study of ocular inflammation after COVID-19 vaccination. Jpn J Ophthalmol 2023;67(1):14-21. PMID 36417027
199: Ye X, Zhang H, Xiao P, et al. Microvasculature features of Vogt-Koyanagi-Harada disease revealed by widefield swept-source optical coherence tomography angiography. Front Med (Lausanne) 2021;8:719593. PMID 34722564
200: Yepez JB, Murati FA, Petitto M, et al. Vogt-Koyanagi-Harada disease following COVID-19 infection. Case Rep Ophthalmol 2021;12(3):804-8. PMID 34720981
201: Yoshida S, Shiraishi K, Mito T, Sayama K. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma. Clin Exp Dermatol 2020;45(7):908-11. PMID 32394515
202: Yoshitomi S, Harada Y, Hiyama T, Yuasa Y, Hirooka K, Kiuchi Y. Incidence and pre/post-treatment risk factors of glaucoma in Vogt-Koyanagi-Harada disease. Int Ophthalmol 2023;43(8):2857-66. PMID 36929369
203: Zhang Q, Fan X, Tian M, Han H. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome. BMC Nephrol 2020;21(1):272. PMID 32660433
204: Zhang W, Chen Z, Yi K, et al. TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 response in association with downregulated Treg response in Vogt-Koyanagi-Harada disease. Clin Immunol 2023;250:109323. PMID 37019422
205: Zhang Y, Deng Y, Jing S, et al. Proteomic profiling of aqueous humor-derived exosomes in Vogt-Koyanagi-Harada disease and Behcet's uveitis. Clin Immunol 2024;259:109895. PMID 38185270
206: Zheng H, Yang F, Ea V, et al. Proteomics profiling of plasma exosomes in VKH patients. Curr Mol Med 2021;21(8):675-89. PMID 32682377
207: Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease. Nat Commun 2023;14(1):3768. PMID 37355662
208: Zhou C, Cai S, Xie Y, et al. Genetic association of PRKCD and CARD9 polymorphisms with Vogt-Koyanagi-Harada disease in the Chinese Han population. Hum Genomics 2023;17(1):9. PMID 36782298
209: Zmuda M, Tiev KP, Knoeri J, Heron E. Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2013;21(4):310-6. PMID 23617262

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Homer Chiang MD

Dr. Chiang of Kaiser Permanente Santa Clara Homestead Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Jonathan D Trobe MD

Dr. Trobe of the University of Michigan has no relevant financial relationships to disclose.
See Profile

Former Authors

James Goodwin MD
Peter MacIntosh MD
Brooke Johnson DO
Heather E Moss MD PhD

Patient Profile

Age range of presentation: 13 to 65+ years
Sex preponderance: female>male, >1:1
Heredity: heredity may be a factor
Population groups selectively affected: Asians

Indians

Native Americans

Hispanics

African descent
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Other iridocyclitis: H20.8

Vogt-Koyanagi Harada syndrome, bilateral: H20.823
ICD-11: Vogt-Koyanagi-Harada syndrome: ED63.3

Anterior uveitis associated with systemic conditions: 9A96.1

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Vogt-Koyanagi-Harada syndrome

Associated Disorders

HLA-DR4 positivity
combinations of HLA-DR4 and HLA-DR1

Differential Diagnosis

sympathetic ophthalmia
lymphoma
acute lymphoblastic leukemia
sarcoidosis
immune complex–mediated choroidal vasculitis in systemic lupus erythematosus
- infectious posterior uveitis
- syphilis
- tuberculosis
- acute multifocal placoid pigment epitheliopathy
- multiple evanescent white dot syndrome
- posterior scleritis
- Vogt-Koyanagi-Harada–like syndrome
- autoimmune diseases
- ulcerative colitis
- IgA nephropathy
- erosive seronegative polyarthritis

Vogt-Koyanagi-Harada syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Table 1. Consensus Diagnostic Criteria for Vogt-Koyanagi-Harada Disease

Table 2. Proposed New Diagnostic Criteria for Vogt-Koyanagi-Harada Disease

Table 3. Classification Criteria for Early-Stage Vogt-Koyanagi-Harada Disease

Table 4. Classification Criteria for Late-Stage Vogt-Koyanagi-Harada Disease

Management

Outcomes

Special considerations

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-IgLON5 disease

Anti-LGI1 encephalitis

Headache associated with intracranial neoplasms

Giant cell arteritis

Ischemic optic neuropathy

Transient visual loss

Vestibular schwannoma

Ophthalmic electrophysiology

This is an article preview.
Start a Free Account
to access the full version.